Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-111A vs Tafluprost in Open-Angle Glaucoma or Ocular Hypertension
NCT03822559Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jan 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafluprost + timolol in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Change from baseline in the average diurnal intraocular pressure at 3 months. Started Jan 2019; status: completed.
02
Drugs
tafluprost + timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT03822559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822559.